Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Pandemic Influenza Vaccine, Placebo; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza-Like Illness, Influenza
Interventions: Core Lab Test, ED Point of Care Test; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, Influenza A, Influenza B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 2 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Influenza, Influenza A, Influenza B, COVID-19, Respiratory Syncytial Virus (RSV)
Interventions: ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 17,043 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Influenza
Interventions: Oseltamivir, MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Influenza
Interventions: Influenza A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Baltimore, Maryland • Rochester, New York • Nashville, Tennessee

Conditions: Influenza
Interventions: Ca/04/2009/H1N1r Challenge Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza, Human
Interventions: FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more

Conditions: Influenza
Interventions: Influenza virus vaccine (CAIV-T); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Months to 18 Years
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Seasonal Influenza DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more

Conditions: Influenza A Virus Infection
Interventions: High-titer anti-influenza plasma, Low-titer anti-influenza plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Weeks and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Influenza, Human
Interventions: AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device; Biological · Device
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Fort Collins, Colorado • Loveland, Colorado

Conditions: Influenza
Interventions: GSK influenza virus H5N1 vaccine 1557484A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Atlanta, Georgia • Bethesda, Maryland • Silver Spring, Maryland

Conditions: Influenza
Interventions: CAIV-T, TIV, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Influenza
Interventions: Influenza virus vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: H1N1 Influenza Virus
Interventions: H1N1 vaccine high dose, H1N1 vaccine low dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more

Conditions: Influenza A Subtype H5N1 Infection
Interventions: H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine; Biological
Lead sponsor: Access to Advanced Health Institute (AAHI); Other
Eligibility: 18 Years to 49 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Influenza A Virus
Interventions: JNJ-63623872, Placebo, Oseltamivir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Fresno, California • Long Beach, California • Stanford, California + 11 more

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 14 Years to 100 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Influenza
Interventions: Influenza A/Bethesda/MM2/H1N1 Challenge; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 1 more

Conditions: Immunologic Tests
Interventions: Serum samples; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 64 Years
Enrollment: 414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Impact of Rapid Flu Testing in BMC ED

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

A Study of VIS410 to Assess Safety and Pharmacokinetics

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Study of a Flu Vaccine in Children

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Jet Injection for Influenza

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

H5N1 Mix and Match With AS03

H1N1v Virus Challenge Study in Healthy Subjects

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines